PCN79 Cost Effectiveness of Erlotinib in First Line Treatment of Advanced Non Small Cell Lung Cancer (NSCLC) in Vulnerable Elderly Patients- An Economical Analysis of a prospective Phase 2 Study (GFPC 0505)
Abstract
Authors
C. Chouaid H. Le Caer R. Corre J. Crequit H. Jullian L. Falchero C. Dujon A. Vergnenegre